A Single Inhaler Combining a Corticosteroid and Long-Acting Beta-2 Agonist for Maintenance with Additional Doses for Reliever Therapy (SMART): Obstacles for Asthma Patients in the USA

National Heart , Lung, and Blood Institute . 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. J Allergy Clin Immunol, 2020; 146:1217–1270.

Sobieraj DM , Baker WL , Weeda ER , et al. Intermittent Inhaled Corticosteroids and Long-Acting Muscarinic Antagonists for Asthma. Comparative Effectiveness Review No. 194. (Prepared by the University of Connecticut Evidence-based Practice Center under Contract No. 290-2015-00012-I.) AHRQ Publication No. 17(18)-EHC027-EF. Rockville, MD: Agency for Healthcare Research and Quality, 2018. Posted final reports are located on the Effective Health Care Program search page. DOI: https://doi.org/10.23970/AHRQEPCCER194.

Bousquet J , Boulet LP , Peters MJ , et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs high-dose salmeterol/fluticasone. Respir Med, 2007; 101:2437–2446.

Kuna P , Peters MJ , Manjra AI , et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract, 2007; 61:725–736.

Bisgaard H , Le Roux P , Bjamer D , et al. Budesonide/formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma. Chest, 2006; 130:1733–1743.

Sobieraj DM , Weeda ER , Nguyen E , et al. Association of inhaled corticosteroids and long-acting β-agonists as controller and quick relief therapy with exacerbations and symptom control in persistent asthma. A systematic review and meta-analysis. JAMA, 2018; 319:1485–1496.

Patel M , Pilcher J , Pritchard A , et al. Efficacy and safety of maintenance and reliever combination budesonide-formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomized controlled trial. Lancet Respir Med, 2013; 1:32–42.

Thorsson L , Edsbäcker S , Conradson TB . Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI. Eur Respir J, 1994; 7:1839–1844.

Thorsson L , Kenyon C , Newman SP , et al. Lung deposition of budesonide in asthmatics: a comparison of different formulations. Int J Pharm, 1998; 168:119–127.

Palmqvist M , Persson G , Lazer L , et al. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J, 1997; 10:2484–2489.

Palmqvist M , Ibsen T , Mellen A , et al. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am J Respir Crit Care Med, 1999; 160:244–249.